<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845182</url>
  </required_header>
  <id_info>
    <org_study_id>HSC2007243H</org_study_id>
    <nct_id>NCT00845182</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function</brief_title>
  <acronym>PIO-EX</acronym>
  <official_title>Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin
      sensitivity in skeletal muscle, liver, and fat cells. Despite the beneficial effects of
      pioglitazone to improve insulin sensitivity and reduce cardiovascular disease in high risk
      type 2 diabetic patients, weight gain has been a limiting factor. Exenatide, another agent
      used for treatment of T2DM, improves glycemic control and promotes moderate weight loss. In
      this proposal we will examine the effect of combination therapy with pioglitazone plus
      exenatide on body weight, fat topography, beta cell function, glycemic control, and plasma
      lipid levels in subjects with type 2 diabetes mellitus compared to treatment with each drug
      separately. Assessment of beta cell function will be performed by measuring the maximal
      insulin secretory capacity using a maximal hyperglycemic stimulus combined with an
      intravenous arginine stimulus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The thiazolidinedione (TZD) class of drugs has been shown to improve insulin sensitivity in
      skeletal muscle, liver, and adipocytes and to have anti-inflammatory and cardioprotective
      effects. The beta cell function, measured by the insulin secretion/insulin resistance index
      during the OGTT, improves significantly. In the present study, we will perform a more
      definitive assessment of beta cell function in TZD-treated diabetic patients by measuring the
      maximal insulin secretory capacity using a maximal hyperglycemic stimulus combined with an
      intravenous arginine stimulus.

      Despite the beneficial effects of pioglitazone to improve insulin sensitivity and reduce
      cardiovascular events in high risk type 2 diabetic patients, weight gain has been a limiting
      factor for primary care physicians even though pioglitazone treatment leads to a
      redistribution of fat out of muscle/liver/visceral area to subcutaneous fat.

      Exenatide (Byetta) is 39 amino acid peptide which exhibits biological actions similar to
      GLP-1. In clinical trials exenatide reduces HbA1c by 1-1.2% in subjects with type 2 diabetes
      and promotes moderate weight loss which is sustained for up to 2 years.

      In this proposal we will examine the effect of combination therapy with pioglitazone plus
      exenatide on body weight, fat topography, beta cell function, glycemic control, and plasma
      lipid levels in subjects with type 2 diabetes mellitus compared to monotherapy with each
      agent separately. We postulate that combination therapy will result in significant weight
      loss (in contrast to the weight gain which accompanies pioglitazone treatment) and have an
      additive, or even synergistic, effect to improve beta cell function and glycemic control in
      type 2 diabetic patients who are inadequately controlled on oral agent therapy with metformin
      alone, a sulfonylurea alone, or combination of metformin plus a sulfonylurea. We will also
      compare the insulin secretion in healthy control subjects (NGT, n=15) and subjects with
      impaired glucose tolerance (IGT, n=15) to evaluate the relative decline in beta cell function
      in T2DM compared to NGT and IGT subjects. NGT and IGT subjects will participate only in a
      OGTT and a Hyperglycemic clamp- they will not receive any medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Effect of Pioglitazone, Exenatide and combined Pioglitazone and Exenatide on body weight and beta cell function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>change in HbA1c was measured before and after treatment in three groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids</measure>
    <time_frame>6 months</time_frame>
    <description>Effect pioglitazone, exenatide, and pioglitazone plus exenatide on
Insulin sensitivity
Inflammatory cytokines
glucagon and free fatty acids
plasma lipids measured over a 6 month period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Healthy</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide: 15 subjects will be randomized to receive Exenatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Pioglitazone and Drug Exentatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>ACTOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>BYETTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and Exenatide</intervention_name>
    <description>Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months</description>
    <arm_group_label>Drug Pioglitazone and Drug Exentatide</arm_group_label>
    <other_name>ACTOS</other_name>
    <other_name>BYETTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetic patients must be on diet therapy alone or diet plus a sulfonylurea, or diet
             plus metformin, or diet plus sulfonylurea/metformin and have a HbA1c ≥ 7.0%.

          2. Patients must have the following laboratory values:

             Hematocrit ≥ 34 vol% Serum creatinine ≤ 1.8 mg/dl AST (SGOT) ≤ 2 times upper limit of
             normal ALT (SGPT) ≤ 2 times upper limit of normal Alkaline phosphatase ≤ 2 times upper
             limit of normal

          3. Patients must have been on a stable dose of allowed chronic medications for 30 days
             prior to entering the study.

          4. Body weight must be stable (± 3-4 pounds) over the three months prior to study

          5. The normal healthy control group will be age, weight (BMI), and gender matched with
             the diabetic group and must have a normal OGTT according to ADA criteria.

          6. Subjects with IFG/IGT will have a FPG (100-125mg/dl) and/or 2-h plasma glucose
             (140-199mg/dl) according to ADA criteria.

        Exclusion Criteria:

          1. Patients must not have type 1 diabetes.

          2. Patients must not have a fasting plasma glucose of greater than 270 mg/dl or HbA1c &gt;
             10.0%.

          3. Patients must not have received a thiazolidinedione or insulin for more than one week
             during the year prior to randomization.

          4. Patients with a history of clinically significant heart disease (New York Heart
             Classification greater than class 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devjit Tripathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barter Research Center, ALM VA Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <results_first_submitted>April 4, 2013</results_first_submitted>
  <results_first_submitted_qc>March 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes pathogenesis, thiazolidinediones</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>Incretins</keyword>
  <keyword>Insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm</description>
        </group>
        <group group_id="P2">
          <title>Exenatide</title>
          <description>Exenatide: 15 subjects will be randomized to receive Exenatide</description>
        </group>
        <group group_id="P3">
          <title>Pioglitazone and Exentatide</title>
          <description>Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm</description>
        </group>
        <group group_id="B2">
          <title>Exenatide</title>
          <description>Exenatide: 15 subjects will be randomized to receive Exenatide</description>
        </group>
        <group group_id="B3">
          <title>Pioglitazone and Exentatide</title>
          <description>Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="5.7"/>
                    <measurement group_id="B2" value="54.3" spread="8.5"/>
                    <measurement group_id="B3" value="53.8" spread="9.8"/>
                    <measurement group_id="B4" value="54.2" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight</title>
        <description>Effect of Pioglitazone, Exenatide and combined Pioglitazone and Exenatide on body weight and beta cell function</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>we analyzed the weight at the end of study completion</population>
        <group_list>
          <group group_id="O1">
            <title>PIOGLITAZONE</title>
            <description>PIO therapy led to a weigh gain of 5.5 kg</description>
          </group>
          <group group_id="O2">
            <title>EXENATIDE</title>
            <description>PIO therapy led to a weigh loss of 2.4 kg</description>
          </group>
          <group group_id="O3">
            <title>PIOGLITAZONE and EXNATIDE</title>
            <description>Combinatiton of PIoglitazone and Exenatide led to weight gain of 2.7 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight</title>
          <description>Effect of Pioglitazone, Exenatide and combined Pioglitazone and Exenatide on body weight and beta cell function</description>
          <population>we analyzed the weight at the end of study completion</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="7.3"/>
                    <measurement group_id="O2" value="2.4" spread="2.8"/>
                    <measurement group_id="O3" value="2.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HbA1c</title>
        <description>change in HbA1c was measured before and after treatment in three groups</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>There was a greater improvement in HbA1c from baseline after combined treatment with Pioglitazone and Exenatide when compared with either therapy alone.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
Pioglitazone: Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months</description>
          </group>
          <group group_id="O2">
            <title>Exenatide</title>
            <description>Exenatide: 15 subjects will be randomized to receive Exenatide
Exenatide: Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months</description>
          </group>
          <group group_id="O3">
            <title>Drug Pioglitazone and Drug Exentatide</title>
            <description>Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
Pioglitazone and Exenatide: Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <description>change in HbA1c was measured before and after treatment in three groups</description>
          <population>There was a greater improvement in HbA1c from baseline after combined treatment with Pioglitazone and Exenatide when compared with either therapy alone.</population>
          <units>percent point decrease from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.68"/>
                    <measurement group_id="O2" value="1.09" spread="0.68"/>
                    <measurement group_id="O3" value="1.91" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids</title>
        <description>Effect pioglitazone, exenatide, and pioglitazone plus exenatide on
Insulin sensitivity
Inflammatory cytokines
glucagon and free fatty acids
plasma lipids measured over a 6 month period</description>
        <time_frame>6 months</time_frame>
        <population>Data were not collected for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatid</title>
            <description>Effect pioglitazone, exenatide, and pioglitazone plus exenatide on
Insulin sensitivity
Inflammatory cytokines
glucagon and free fatty acids
plasma lipids measured over a 6 month period</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids</title>
          <description>Effect pioglitazone, exenatide, and pioglitazone plus exenatide on
Insulin sensitivity
Inflammatory cytokines
glucagon and free fatty acids
plasma lipids measured over a 6 month period</description>
          <population>Data were not collected for this analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed for 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm</description>
        </group>
        <group group_id="E2">
          <title>Exenatide</title>
          <description>Exenatide: 15 subjects will be randomized to receive Exenatide</description>
        </group>
        <group group_id="E3">
          <title>Pioglitazone and Exentatide</title>
          <description>Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <description>2 patients in the Pioglitazone had weight gain &gt;10kg</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>one patientin exenatide group had persistent nausea and dropped out</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Devjit Tripathy</name_or_title>
      <organization>UTexas_SanAntonio</organization>
      <phone>2105676691</phone>
      <email>tripathy@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

